Skip to main content

Advertisement

SpringerLink
Log in

Down's syndrome and Alzheimer's disease: towards secondary prevention

  • Comment
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

Abstract

A public–private partnership to establish biomarkers of dementia in Down's syndrome could aid the development of preventive therapies for the dementia associated with both Down's syndrome and Alzheimer's disease, based on the apparent common pathogenic role of amyloid precursor protein in the two conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99 (2012).

    Article  CAS  Google Scholar 

  2. Zigman, W., Silverman, W. & Wisniewski, H. M. Aging and Alzheimer's disease in Down syndrome: clinical and pathological changes. Mental Retard. Dev. Disabilities Res. Rev. 2, 73–79 (1996).

    Article  Google Scholar 

  3. Zigman, W. B. & Lott, I. T. Alzheimer's disease in Down syndrome: neurobiology and risk. Mental Retard. Dev. Disabilities Res. Rev. 13, 237–246 (2007).

    Article  Google Scholar 

  4. Shi, Y. et al. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 4, 124ra29 (2012).

    PubMed  PubMed Central  Google Scholar 

  5. Barker, A. D. et al. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin. Pharmacol. Ther. 86, 97–100 (2009).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

W. P. Battisti (Janssen Research & Development, USA) provided administrative and editorial support for this manuscript.

Author information

Authors and Affiliations

  1. Seth Ness, Michael Krams and Husseini Manji are at Janssen Research & Development, 1125 Trenton-Harbourton Road, Raritan, New Jersey 08560, USA.,

    Seth Ness, Michael Krams & Husseini Manji

  2. Michael Rafii and Paul Aisen are at the University of California San Diego, La Jolla, California 92093, USA.,

    Michael Rafii & Paul Aisen

  3. Wayne Silverman is at the Kennedy Krieger Institute and Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.,

    Wayne Silverman

Authors
  1. Seth Ness
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Rafii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Aisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Krams
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wayne Silverman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Husseini Manji
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seth Ness.

Ethics declarations

Competing interests

Seth Ness, Michael Krams and Husseini Manji are full-time employees of Johnson & Johnson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ness, S., Rafii, M., Aisen, P. et al. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov 11, 655–656 (2012). https://doi.org/10.1038/nrd3822

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3822

  • Springer Nature Limited

This article is cited by

Search

Navigation